WinSanTorâs mission is simple-develop a drug that works. We recognize that there are no treatments for this disease today. Thus, WinSanTor is striving to impact the lives of todayâs patients heavily burdened by peripheral neuropathy. We are impatient. We are exploiting every strategy, mechanism, and regulation to accelerate approval of our drugs, including recycling a previously approved safe drug. Phase 1 is complete and we are now starting phase 2. Our goal is to get drug approval in the US by 2021 and perhaps sooner elsewhere. By focusing on patient impact rather than the bottom line, we believe weâre creating a new sustainable model for pharma companies based on patient need, not just money. Source
No articles found.
Celcuity is a cellular analysis company that is discovering new cancer sub-types a...
Celcuity is a cellular analysis company that is...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...
Incyte Corporation is a Wilmington, Delaware-ba...
We are developing nalbuphine ER to treat serious neurologically mediated condition...
We are developing nalbuphine ER to treat seriou...
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...
Cyclacel's founding scientist, Professor Sir Da...
The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...
The mission of Cassava Sciences is to detect an...
Join the National Investor Network and get the latest information with your interests in mind.